# US 9,433,805 B2 · Method for dermal regeneration by administering an ether cross-linked glucomannan/hyaluronic acid composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,433,805 B2
- Document ID: US9433805B2
- Status: Granted
- Kind: B2
- Application number: 12/681,391
- Filed: 2008-10-03
- Published: 2010-10-07
- Granted: 2016-09-06
- Earliest claimed: 2007-10-04
- Assignees: Ultraceuticals R & D Pty Ltd
- Applicants: Geoffrey Heber; Nicholas Patrick John Stamford
- Inventors: Geoffrey Heber; Nicholas Patrick John Stamford
- Web page: https://patentgrep.com/patent/US9433805B2

## CPC

- A61K 8/73: Polysaccharides
- A61K 8/0241: {Containing particulates characterized by their shape and/or structure (see also A61K8/04, A61K8/11, and A61K8/14, further aspects are classified in A61K2800/40 and subcodes)}
- A61K 8/042: {Gels}
- A61K 8/735: {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- A61K 8/736: {Chitin; Chitosan; Derivatives thereof}
- A61K 31/736: Glucomannans or galactomannans, e.g. locust bean gum, guar gum
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/412: Microsized, i.e. having sizes between 0.1 and 100 microns
- A61K 2800/56: Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
- A61K 2800/91: Injection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to glucommannan oligosaccharides and polysaccharides that possess one or more properties selected from skin regeneration, wound healing and skin augmentation. More particularly, the invention relates to the use of glucomannan oligosaccharides and polysaccharides for one or more of skin regeneration, wound healing and skin augmentation agents in a mammal. The invention also relates to a pharmaceutical formulation for treating skin of a subject comprising an active component comprising glucomannan in a suitable diluent, excipient or physical form such as dermal scaffold or sponge, the active component being capable of promoting an accumulation of fibroblasts in the skin and stimulating production of collagen in the skin.

## Claims

### Claim 1

A method for treating a condition of skin of a mammalian subject in need of such treatment by promoting an accumulation of fibroblasts in the skin and increasing production of collagen in skin, the method comprising delivering to the skin of the subject an active component comprising:
a glucomannan polysaccharide cross linked with hyaluronic acid, or an oligosaccharide derived from glucomannan cross linked with hyaluronic acid, or mixtures or combinations thereof;
wherein the glucomannan polysaccharide or the oligosaccharide derived from glucomannan is derived from konjac root (Amorphophallus konjac);
wherein the glucomannan polysaccharide or the oligosaccharide derived from glucomannan is cross-linked with the hyaluronic acid by ether bonds using a bifunctional epoxide or a polyfunctional epoxide cross-linking agent;
wherein the active component is formulated as a gel, or with an encapsulation vehicle, liposome, or particulate or microfine vehicle, and
wherein the treating is selected from the group consisting of regenerating, healing, augmenting, reducing scarring, reducing signs of ageing, heals wounds or ulcers, regenerating atrophic skin due to trauma, skin disease or skin ageing, smoothing wrinkles, increasing skin firmness, and increasing elasticity in ageing skin.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the active component is a glucomannan polysaccharide cross linked with hyaluronic acid.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the active component comprises glucomannan polysaccharide cross linked with hyaluronic acid, oligosaccharide derived from glucomannan cross linked with the hyaluronic acid, mixtures or combinations thereof, and the hyaluronic acid is in a ratio of 90:10 by weight to 10:90 by weight.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the active component comprises glucomannan polysaccharide cross linked with hyaluronic acid or an oligosaccharide derived from glucomannan cross linked with hyaluronic acid, wherein the hyaluronic acid is in a ratio of 20:80 by weight.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the active component is injected directly into the skin or subcutaneous tissue of the subject.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the active component is applied topically to the skin of the subject.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the active component is delivered to the skin of the subject at a concentration of from 0.001 to 100% by weight.

### Claim 8 (depends on 3)

The method of claim 3, wherein the ratio of glucomannan polysaccharide or oligosaccharide derived from glucomannan and hyaluronic acid is 15:85 by weight.

### Claim 9 (depends on 3)

The method of claim 3, wherein the ratio of glucomannan polysaccharide or oligosaccharide derived from glucomannan and hyaluronic acid is 10:90 by weight.

### Claim 10 (depends on 1)

The method of claim 1, wherein the active component is delivered to the skin of the subject at a concentration of from 0.01 to 70% by weight.

### Claim 11 (depends on 1)

The method of claim 1, wherein the active component is delivered to the skin of the subject at a concentration of from 1 to 20% by weight.

### Claim 12 (depends on 1)

The method of claim 1, wherein the active component comprises glucomannan polysaccharide cross linked with hyaluronic acid.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the hyaluronic acid is in a ratio of 90:10 by weight to 10:90 by weight.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the hyaluronic acid is in a ratio of 85:15 by weight.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the active component is injected directly into the skin or subcutaneous tissue of the subject.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the active component is applied topically to the skin of the subject.

### Claim 17 (depends on 14)

The method according to claim 14, wherein the active component is delivered to the skin of the subject at a concentration of from 0.001 to 100% by weight.

### Claim 18 (depends on 1)

The method according to claim 1 wherein the cross-linking agent is 1,4 butanediol diglycidyl ether.